Company
Headquarters: Watertown, MA, United States
Employees: 141
CEO: Dr. Nello Mainolfi M.D., Ph.D.
$5.82 Billion
USD as of Jan. 1, 2026
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $158.96 B |
| Vertex Pharmaceuticals Incorporated | $115.92 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $82.28 B |
| Marinomed Biotech AG | $70.11 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
| Last Financial Reports Date | Sept. 30, 2025 |
| Revenue TTM | $43.7 M |
| EBITDA | $-321,535,008 |
| Gross Profit TTM | $-260,819,008 |
| Profit Margin | 0.00% |
| Operating Margin | -3207.89% |
| Quarterly Revenue Growth | -26.10% |
Kymera Therapeutics, Inc. has the following listings and related stock indices.
Stock: NASDAQ: KYMR